Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,352 Shares of Stock

08 Jan 2026, 19:52 by Jessica Moore · The Cerbat Gem

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Eric Pauwels sold 1,352 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $77.48, for a total transaction of $104,752.96. Following the sale, the insider owned 87,489 shares of the company’s stock, valued at approximately $6,778,647.72. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Pauwels also recently made the following trade(s):

On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $137,663.55.
On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.26, for a total transaction of $1,584,448.08.
On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.43, for a total transaction of $3,039,074.70.
On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Price Performance

NASDAQ PTCT traded down $0.39 during trading hours on Thursday, reaching $76.85. 1,625,361 shares of the stock traded hands, compared to its average volume of 1,684,365. The stock has a 50 day simple moving average of $76.26 and a two-hundred day simple moving average of $62.43. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company has a market cap of $6.17 billion, a price-to-earnings ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The firm had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.39) EPS. On average, sell-side analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Institutional Investors Weigh In On PTC Therapeutics

A number of large investors have recently made changes to their positions in PTCT. Empowered Funds LLC purchased a new stake in PTC Therapeutics in the first quarter worth $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of PTC Therapeutics by 11.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after purchasing an additional 18,504 shares during the period. Bayforest Capital Ltd bought a new stake in shares of PTC Therapeutics during the 1st quarter valued at about $415,000. Intech Investment Management LLC raised its stake in PTC Therapeutics by 62.8% in the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock worth $2,003,000 after buying an additional 15,167 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in PTC Therapeutics by 6.1% in the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock worth $1,904,000 after buying an additional 2,140 shares during the period.

Wall Street Analyst Weigh In

Several research firms have weighed in on PTCT. The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research note on Wednesday, November 5th. Morgan Stanley reissued an “overweight” rating and issued a $90.00 target price on shares of PTC Therapeutics in a research note on Thursday. Citigroup lifted their price target on PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Wells Fargo & Company increased their price objective on PTC Therapeutics from $73.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics currently has a consensus rating of “Hold” and an average price target of $77.27.

Get Our Latest Research Report on PTC Therapeutics

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.